A mouse model of ovarian cancer has shown that in vivo treatment with single agent antibodies against PD-1, CTLA-4, or LAG-3 leads to compensatory upregulation of other checkpoint inhibitor pathways in tumour-associated lymphocytes. Here, CTLA4 is linked to neoplasm.